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ABSTRACT The rapid fosfomycin/Escherichia coli NP test was developed to detect
fosfomycin resistance in E. coli isolates. The test is based on glucose metabolization
and the detection of bacterial growth in the presence of fosfomycin at 40 g/ml.
Bacterial growth is visually detectable by an orange-to-yellow color change of red
phenol, a pH indicator. A total of 100 E. coli isolates, among which 22 were fosfomy-
cin resistant, were used to evaluate the test performance. The sensitivity and speci-
ﬁcity of the test were 100% and 98.7%, respectively. This new test is user friendly,
sensitive and speciﬁc, and its results are obtained in 1 h 30 min.
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Multidrug resistance in Enterobacteriaceae spp. represents a serious threat to publichealth, since the accumulation of resistance determinants may be the source of
difﬁcult-to-treat infections in humans. The increase of multidrug-resistant (MDR) bac-
teria induced a renewed interest in old antibiotics, such as fosfomycin (1). Because of
its broad-spectrum activity and its safety proﬁle, fosfomycin is often used as a ﬁrst-line
antibiotic for treating uncomplicated urinary tract infections (UTIs) (2).
Escherichia coli, which is the bacterial species most frequently responsible for UTIs,
exhibits an increased resistance rate to broad-spectrum cephalosporins through the
production of extended-spectrum -lactamases (ESBLs) but often remains susceptible
to fosfomycin (3). However, the fosfomycin resistance rate in E. coli might also be
increasing due to an increased clinical use and, consequently, an increased selective
pressure.
In Gram-negative bacteria, fosfomycin resistance can result from reduced permea-
bility, amino acid mutations in the active site of the MurA target involved in pepti-
doglycan biosynthesis, and the production of fosfomycin-inactivating enzymes (fos
genes) (4). Acquired resistance to fosfomycin in E. coli may be due to metalloenzymes
of the FosA type that catalyze the conjugation of glutathione to fosfomycin, thereby
inactivating this antibiotic (5). The FosA3 enzyme is the most commonly identiﬁed
FosA-like determinant found as an acquired mechanism of fosfomycin resistance in E.
coli, and it is quite widespread in East Asia (6–8). The fosA3 gene is usually located in
conjugative plasmids also carrying CTX-M-type ESBL-encoding genes (9, 10). Conse-
quently, E. coli strains acquiring such plasmids usually exhibit coresistance to both
fosfomycin and broad-spectrum cephalosporins. Although less frequently, fosA4, fosA5,
and fosA6 genes have also been identiﬁed in E. coli (9, 11, 12). In addition, the
acquisition of the fosA1 gene has been reported in Serratia marcescens, and a chromo-
somal fosA2 gene has been identiﬁed in Enterobacter cloacae (13, 14).
Since fosfomycin is being used as an empirical treatment for UTIs in the community
and also for severe hospital-acquired infections, there was an interest to develop a
rapid test to evaluate its efﬁcacy. The standard reference technique for determining
susceptibility to fosfomycin is based on agar dilution that is a tedious technique
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requiring 18  2 h to be performed (15). Other techniques, such as disk diffusion and
Etest strips, can also be used, but they also require at least 18 h (16, 17).
In order to rapidly identify fosfomycin-resistant E. coli isolates, we aimed to develop
a rapid and cost-effective test that might be used worldwide, regardless of the technical
level of the laboratory. Similar to the recently developed Rapid Polymyxin NP test (18),
we have developed the rapid fosfomycin/E. coli NP test which is a user-friendly
technique based on carbohydrate hydrolysis detecting bacterial growth (or absence of
growth) in the presence of a deﬁned concentration of fosfomycin, allowing the rapid
detection (1 h 30 min) of fosfomycin-resistant E. coli isolates.
MATERIALS AND METHODS
Isolate collection. A total of 100 E. coli isolates collected from clinical samples worldwide were used.
This collection included 22 fosfomycin-resistant isolates, consisting of 14 isolates with acquired resistance
to fosfomycin due to the fosA3 gene and 8 isolates with an unknown mechanism of resistance. The other
78 E. coli isolates were susceptible to fosfomycin (Table 1).
MIC determination. To determine MIC values for fosfomycin, we used the agar dilution method in
cation-adjusted Mueller-Hinton agar (MHA-CA, reference 64884; Bio-Rad, Marnes-La-Coquette, France)
supplemented with 25 g/ml of glucose-6-phosphate, as recommended by Clinical and Laboratory
Standards Institute (CLSI) guidelines (14). We considered this technique to be the standard for compar-
ison with the results obtained with the rapid fosfomycin/E. coli NP test. Fosfomycin (reference 34089;
Sigma-Aldrich, St. Louis, MO, USA) was tested over a range of dilutions (1 to 512 g/ml). All experiments
were repeated in three separate experiments, using daily freshly prepared plates and inoculums.
The breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) were
used as reference (19). Hence, E. coli isolates with fosfomycin MICs of 32 g/ml were categorized as
susceptible, while those with MICs of 32 g/ml were categorized as resistant.
PCR ampliﬁcation and sequencing. DNA of the isolates was recovered using the QIAamp DNA mini
kit and the QIAcube workstation (Qiagen, Courtaboeuf, France), according to the manufacturer’s instruc-
tions. PCR ampliﬁcation was performed to detect the plasmid-mediated fosA1 to fosA6 genes with the
following primers: fosA1-2_Fw (5=-STAYGACGAGGCGCGCSRKTACGTG-3=), fosA3-4_Fw (5=-CTGGATGMGC
AGCGGCGTAAAACG-3=), fosA5-6_Fw (5=-CCGCAGCGGCGCGTTACTCCGCCG-3=), and fosA_Univ_Rv (5=-CRTC
VGGRTCGAGRAAATAG-3=). The PCR conditions were 98°C for 1 min; followed by 35 cycles of 98°C for 1 s,
55°C for 30 s, and 72°C for 30 s; with a ﬁnal extension of 72°C for 10 min. Enterobacter cloacae R2969,
Kluyvera georgiana R1108, and Klebsiella pneumoniae R2292 were used as controls for plasmids carrying
fosA1 to 2, fosA3 to 4, and fosA5 to 6 genes, respectively. To discriminate between fosA3 and fosA4,
positive PCRs were further sequenced by Microsynth (Balgach, Switzerland) and results analyzed with
CloneManager Professional (Sci-Ed software, Denver, CO, USA).
Rapid fosfomycin/E. coli NP test. Reagents and solutions. The rapid fosfomycin/E. coli NP test
requires two reagents and solutions, namely the stock solutions of fosfomycin and the rapid fosfomycin
NP solution, as described below. For stock solutions of fosfomycin, powder was diluted into Milli-Q water
TABLE 1 Rapid fosfomycin NP/E. coli test results for fosfomycin-resistant and fosfomycin-susceptible E. coli isolates
Origin Fosfomycin phenotypea MIC (g/ml) Rapid fosfomycin NP test Resistance mechanism No. of isolates
China R 512  fosA3 4
Switzerland R 512  fosA3 5
Nepal R 512  fosA3 2
France R 512  fosA3 1
South Africa R 512  fosA3 2
Switzerland R 64  fosA1–6 not detected 1
Switzerland R 128  fosA1–6 not detected 1
Switzerland R 512  fosA1–6 not detected 6
China S 1  NAb 7
Switzerland S 1  NA 9
Switzerland S 1  NA 1
Switzerland S 16  NA 2
France S 1  NA 53
Lebanon S 16  NA 1
Inde S 1  NA 2
France S 16  NA 1
France S 32  NA 1
Angola S 1  NA 1
Switzerlandc R 512  fosA1–6 not detected 1
Switzerlandd S 1  NA 1
aR, resistant; S, susceptible.
bNA, not applicable. Fosfomycin-susceptible strains were not investigated for the presence of fosA genes.
cPositive control isolate N279.
dNegative control isolate N6.
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to obtain a concentration of 50 mg/ml. This solution can be stored for 1 month at 4°C. The rapid
fosfomycin NP solution was prepared by mixing the culture medium, the pH indicator, and the distilled
water. The pH was further adjusted to 7.5 and the solution autoclaved to obtain a ﬁnal concentration of
2.5% MHB-CA powder, 0.005% phenol red indicator, and 1% D()-glucose. This solution can be kept at
4°C for 1 week or at20°C for 1 year and must be prewarmed at 37°C before use to prevent growth delay
and a delayed color change. Before performing the experiment, fosfomycin was added to the rapid
fosfomycin NP solution and mixed to obtain a ﬁnal fosfomycin concentration at 40 g/ml.
Bacterial inoculum preparation. A standardized E. coli inoculum was prepared by using freshly
obtained (overnight) bacterial colonies grown on UriSelect 4 agar plates, as previously described (17).
Bacterial colonies were resuspended into 5 ml of sterile NaCl (0.85%) to obtain a 3.0 to 3.5 McFarland
standard optical density (109 CFU/ml). A bacterial suspension was prepared for each isolate to be tested
(Table 1).
Tray inoculation and reading. Inoculation and reading were performed similarly to what is
recommended for the optimized Rapid Polymyxin NP test (18). Brieﬂy, a 96-well polystyrene microtest
plate (round base with lid, sterile, reference 82.1582.001; Sarstedt, Nümbrecht, Germany) was used to
inoculate the bacterial suspension in the presence or absence of fosfomycin, in separate wells. A total of
50 l of bacterial suspension was added to two wells, the ﬁrst containing 150 l of rapid fosfomycin NP
solution without fosfomycin, and the second containing 150 l of rapid fosfomycin NP solution
supplemented with 25 g/ml glucose-6-phosphate and 40 g/ml fosfomycin. The same procedure was
performed using 50 l NaCl instead of the bacterial suspension, as a negative control. The ﬁnal
concentration of bacteria was 108 CFU/ml in each well, and the ﬁnal concentration of fosfomycin was
40 g/ml. Each sample was tested in duplicate.
The trays were visually inspected every 30 min. Isolates N6 and N279 were used as negative and
positive controls, respectively (Table 1). A test result was considered positive (fosfomycin resistance) if the
isolate grew in the presence of fosfomycin, when a color change from orange to yellow was observed
in the wells, conﬁrming the metabolism of glucose by the isolate (Fig. 1). Conversely, a test result was
considered negative (fosfomycin susceptibility) if the isolate did not grow in the presence of fosfomycin,
meaning the color of the wells remained orange.
RESULTS
A total of 100 E. coli isolates were tested to evaluate the performance of the rapid
fosfomycin/E. coli NP test. Among the 22 fosfomycin-resistant isolates, 14 exhibited the
acquired mechanism of resistance to fosfomycin FosA3, while 8 were negative for fosA1
to fosA6 gene ampliﬁcation. Other mechanisms of resistance to fosfomycin were not
further investigated.
The 78 fosfomycin-susceptible isolates (MICs of fosfomycin, 1 to 32 g/ml) gave
negative results with the rapid fosfomycin/E. coli NP test, except for a single isolate
(isolate N13 showing an MIC value of fosfomycin of 1 g/ml) which gave a positive
FIG 1 Rapid fosfomycin NP/E. coli test, representative results. The ﬁrst row shows noninoculated wells,
containing the rapid fosfomycin NP solution and NaCl. In columns 2 and 4, the solution was supple-
mented with fosfomycin (FOS). The second row shows the negative (C) and the positive (C)
controls. The third row shows two tested samples, N23 and Un421. As C, N23 isolate grew (yellow color)
in the absence of fosfomycin and did not grow (orange color) in the presence of this antibiotic. Thus, it
was thus as fosfomycin susceptible. Isolate Un421 and C grew in presence and absence of fosfomycin,
and Un421 was reported to be fosfomycin resistant. Note that in the absence of bacterial suspension, the
well color is pink, while the inoculated wells exhibit an orange color in the absence of bacterial growth.
However, this color difference did not compromise the interpretation of the test results.
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result (major error) (Table 1). All the fosfomycin-resistant isolates that carried an
acquired fosA3 gene (n  14; MICs of fosfomycin, 512 g/ml) or for which the
mechanism of resistance remains unknown (n  8; MICs of fosfomycin, 64 to 512
g/ml) had a positive test result (Table 1).
There was a strong agreement between the results of the susceptibility test and of
the rapid fosfomycin/E. coli NP test, both for susceptible and resistant isolates (Table 1).
The sensitivity and speciﬁcity were found to be 100% and 98.7%, respectively.
By reading the color change of the wells every 30 min after incubation, we
determined that ﬁnal results could be obtained after 1 h 30 min of incubation at 35 
2°C.
Additionally, 10 isolates of K. pneumoniae were evaluated by means of this test, 5 of
which were fosfomycin susceptible and 5 of which were fosfomycin resistant. A low
correlation between the rapid fosfomycin/E. coli NP test and the agar dilution method
was observed. In fact, all samples were found positive with the rapid fosfomycin/E. coli
NP test, thereby giving a poor and unacceptable speciﬁcity (50%).
DISCUSSION
The rapid fosfomycin/E. coli NP test is a rapid and easy-to-perform test, combining
excellent sensitivity and speciﬁcity. It detects fosfomycin resistance in E. coli regardless
of the molecular mechanism of resistance. This test offers the possibility of detecting
fosfomycin resistance from bacterial cultures in 1 h 30 min, which is at least 16 h earlier
than with the reference agar dilution method. Even though a discrepancy was observed
by using this test (one major error), the sensitivity and speciﬁcity remained high,
making it a potential useful clinical test.
As for the Rapid Polymyxin NP test, we believe that the rapid fosfomycin/E. coli NP
test might be useful for ﬁrst-step screening, in this case for fosfomycin resistance in E.
coli. This use is particularly interesting in a context of increased prevalence of ESBL
producers among which resistance to fosfomycin seems to be higher than that ob-
served for non-ESBL producers, with susceptibility rates of 86% and 97%, respectively,
as reported in a study from Lebanon (20). Overall, the susceptibility rate of fosfomycin
in E. coli (ESBL- and non-ESBL producers) is estimated to be around 90% (21).
Such a test might be useful, considering that the use of molecular-based approaches
for the detection of fosfomycin resistance in E. coli is not possible. Indeed, a series of
known resistance mechanisms cannot be detected by molecular biology, such as a loss
of active transport mechanisms or mutations in the fosfomycin target gene murA (4).
However, the rapid fosfomycin/E. coli NP test presents some limitations. The inter-
pretation of color changes is made visually. Therefore, despite that resistant isolates
show a clear switch from orange to yellow, low-level resistance isolates (MICs, 64 and
128 g/ml; e.g., isolates N140 or N181) might need a more accurate reading and/or a
second reader. In addition, this test does not allow discrimination between chromo-
somally encoded and acquired fosfomycin resistance mechanisms. Finally, another
shortcoming of the test could be that it may only be applied to E. coli so far. Since
preliminary results with K. pneumoniae isolates showed a poor speciﬁcity of the test, we
hypothesize that this might be due to the occurrence of fosfomycin-resistant mutants,
perhaps showing mutations in an intrinsic chromosomal gene which is homologous to
fosA in that species. This test would beneﬁt from a multicenter evaluation. Finally, since
E. coli is responsible for more than 75% of UTIs (22), the test responds to most of the
clinical need for rapidly choosing an optimal treatment for this infection as well as for
UTI-associated septicemia.
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